Last quarter (Q2 2022), ImmuPharma's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, ImmuPharma's net income was £―. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	£ 118.35K	£ 126.67K	£ 77.92K	£ 81.28K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	-	£ 3.03M	£ 5.28M	£ 5.72M	£ 6.36M	£ 8.16M
Operating Income	-	£ -3.03M	£ -5.16M	£ -5.59M	£ -6.28M	£ -8.08M
Net Non Operating Interest Income Expense	-	£ -1.13K	£ 205.25K	£ -395.02K	£ 1.70K	£ 7.71K
Other Income Expense	-	£ 1.41M	-	-	-	-
Pretax Income	-	£ -4.46M	£ -8.94M	£ -7.25M	£ -6.74M	£ -7.96M
Tax Provision	-	£ -648.90K	£ -766.81K	£ -386.25K	£ -620.77K	£ -748.61K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -3.81M	£ -8.17M	£ -6.86M	£ -6.12M	£ -7.21M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 3.03M	£ -5.28M	£ 5.72M	£ 6.36M	£ 8.16M
Net Income From Continuing And Discontinued Operation	-	£ -3.81M	£ -8.17M	£ -6.86M	£ -6.12M	£ -7.21M
Normalized Income	-	£ -5.11M	£ -8.28M	£ -5.80M	£ -6.18M	£ -7.21M
Interest Expense	-	-	-	£ 230.83K	£ 4.04K	£ 4.78K
EBIT	-	£ -4.45M	£ -8.82M	£ -7.02M	£ -6.74M	£ -7.95M
EBITDA	-	£ -4.34M	£ -8.82M	£ -6.84M	£ -6.65M	£ -7.82M

Currency in GBP

ImmuPharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing